The HIRA said that the cost-effectiveness evaluation criteria for omitted drugs that submit economic evaluation data are less than 80% of the lowest A7 adjustment price. It also explained that the economical evaluation drug can be integrated into a risk-sharing system (RSA), which can set the indicator price higher than the lowest A7 price in case of refundable restrictions.

On the 2nd, The HIRA responded like this to a written inquiry from Rep. Kim Mi-ae of the National Assembly. Rep. Kim Mi-ae pointed out that it is necessary to disclose the internal regulations of The HIRA on the criteria for lowering the level of cost-effectiveness evaluation of economic evaluation drugs. Rep. Kim also asked The NHI